Shopping Cart
- Remove All
Your shopping cart is currently empty
CNS-5161 hydrochloride (CNS 5161A) is a new antagonist of NMDA ion-channel. It interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $509 | In Stock | |
| 5 mg | $1,000 | In Stock | |
| 10 mg | $1,360 | In Stock | |
| 25 mg | $2,020 | In Stock | |
| 50 mg | $2,710 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,150 | In Stock |
| Description | CNS-5161 hydrochloride (CNS 5161A) is a new antagonist of NMDA ion-channel. It interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate. |
| Targets&IC50 | NMDA:1.8 nM (Ki) |
| In vitro | CNS-5161 has potent inhibitory activity in vitro at the NMDA ion channel and is able to displace [3H] MK-801 binding with a Ki of 1.8 nM in synaptosomal membrane preparations from rat brain. |
| In vivo | In the neonatal rat NMDA excitotoxicity model in vivo, CNS-5161 (i.p.) protects against the necrotic effects of exogenous N-methyl-D-aspartate (ED80: 4 mg/kg). CNS-5161 also demonstrates a 91% inhibition of audiogenic seizures in DBA/2 mice at 4 mg/kg i.p. and exhibits neuroprotective effects following hypoxic/ischaemic brain injury in neonatal rats[1]. |
| Synonyms | CNS 5161A |
| Molecular Weight | 388.38 |
| Formula | C16H19Cl2N3S2 |
| Cas No. | 160756-38-7 |
| Smiles | Cl.ClC1=CC=C(SC)C=C1NC(=N)N(C=2C=CC=C(SC)C2)C |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 245 mg/mL (630.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.